ArticleDigestive diseases and sciences2017
Rapid Fecal Calprotectin Test and Symptom Index in Monitoring the Disease Activity in Colonic Inflammatory Bowel Disease.
Article in Digestive diseases and sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 38 citations in OpenAlex.
- Health-related quality of life and self-reported health status in adolescents with chronic health conditions before transfer of care to adult health care: an international cohort study.BMC pediatrics · 2024Trial
- Evaluation of relationship between endoscopic activity index and inflammatory indicators such as fecal calprotectin, C-reactive protein to albumin ratio, neutrophil to lymphocyte ratio, platelet to lymphocyte ratio in ulcerative colitis patients.Journal of medical biochemistry · 2026Article
- Combined [European journal of nuclear medicine and molecular imaging · 2026Observational
- Switching to Subcutaneous Infliximab Maintenance Therapy Is Effective in Patients with Inflammatory Bowel Disease.Digestive diseases and sciences · 2025Article
- Correlation of a clinical activity index in comparison to frequently measured laboratory values in inflammatory bowel disease.International journal of colorectal disease · 2025Article
- Combined [18F]-Fluorodeoxyglucose Positron Emission Tomography-MR Imaging: A Promising Tool for Diagnostics of Small Bowel Crohn's Disease.Digestive diseases (Basel, Switzerland) · 2025Article
- Anxiety and care experiences in adolescents with chronic health conditions: an international, longitudinal study across the transfer of care.BMJ paediatrics open · 2024Article
- Drug levels of VEDOLIZUMAB in patients with pediatric-onset inflammatory bowel disease in a real-life setting.European journal of pediatrics · 2024Article
- Quantitative Fecal Microbiota Profiles Relate to Therapy Response During Induction With Tumor Necrosis Factor α Antagonist Infliximab in Pediatric Inflammatory Bowel Disease.Inflammatory bowel diseases · 2023Article
- The gut fungal and bacterial microbiota in pediatric patients with inflammatory bowel disease introduced to treatment with anti-tumor necrosis factor-α.Scientific reports · 2022Article
- Disease clearance in ulcerative colitis: Setting the therapeutic goals for future in the treatment of ulcerative colitis.Frontiers in medicine · 2022Review
- A Patient Self-Made Point-of-Care Fecal Test Improves Diagnostic Accuracy Compared with Fecal Calprotectin Alone in Inflammatory Bowel Disease Patients.Diagnostics (Basel, Switzerland) · 2021Article
- Faecal biomarkers in type 1 diabetes with and without diabetic nephropathy.Scientific reports · 2021Article
- Faecal Inflammatory Biomarkers and Gastrointestinal Symptoms after Bariatric Surgery: A Longitudinal Study.Inflammatory intestinal diseases · 2021Article
- From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting.World journal of gastroenterology · 2018Review
- Faecal Calprotectin.The Clinical biochemist. Reviews · 2018Review
- Fecal Calprotectin in Monitoring the Disease Activity in Colonic Inflammatory Bowel Disease.Digestive diseases and sciences · 2017Article
- Optimal Use of Serum Leucine-Rich Alpha-2 Glycoprotein as a Biomarker for Small Bowel Lesions of Crohn's Disease.Inflammatory intestinal diseasesArticle
Corrections and comments
- Commented on by
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFecal calprotectin is a reliable surrogate marker for inflammatory activity in inflammatory bowel disease (IBD).
aimsFor the noninvasive monitoring of the activity of colonic inflammation, we validated a symptom index suitable for ulcerative colitis and colonic Crohn's disease. By combining the symptom index with a rapid semi-quantitative calprotectin test, we constructed a new activity index based on the highest AUCs, using histological remission as a reference. We also evaluated the correlation of the patient-reported influence of the IBD in the daily life, measured by a VAS, with the inflammation activity.
methodsThe disease activity of 72 patients with IBD of the colon was determined by endoscopic activity scores (SES-CD/UCEIS). The patients provided stool samples for determination of calprotectin and filled in a questionnaire about their symptoms during the last week.
resultsThe results of the symptom index demonstrated a statistically significant correlation with the rapid calprotectin test, histological inflammation activity, and the VAS. No correlations were found between the VAS and calprotectin or the histological inflammation activity. The sensitivity of the combination index to detect active inflammation was slightly superior to fecal calprotectin alone.
conclusionThe new symptom index and the combination index are simple, noninvasive means for distinguishing remission from active inflammation in colonic IBD. With the VAS, we can pick up patients who need psychosocial support because of the disease burden, even if their IBD is in remission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.